{
    "nctId": "NCT01427400",
    "briefTitle": "The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction",
    "officialTitle": "The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Skin Diseases",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 128,
    "primaryOutcomeMeasure": "Change from Baseline in Quality of life and patient satisfaction using the Breast-Q",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who undergo immediate, post-mastectomy, unilateral or bilateral, tissue expander/implant reconstruction\n* Patients older than 21, with no upper age limit\n* English-speaking, or has an appropriate translator\n\nExclusion Criteria:\n\n* Patient declines inclusion in the study\n* Patients who undergo a single-stage implant reconstruction or combined autogenous tissue expander/implant reconstruction\n* Previous history of radiation\n* Previous breast surgery with implants\n* Previous history of axillary lymph node dissection\n* Patients who are pregnant\n* Patients with hepatorenal failure\n* Patients with known hypersensitivity to Botulinum Toxin-A\n* Patients with significant mastectomy flap ischemia at time of tissue expander placement",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}